The earnings call reflected a strong market entry for Neffy with notable revenue growth and expanded insurance coverage. Strategic collaborations and a focus on pediatric dosing are positive, but high operating expenses and a net loss remain challenges. Prior authorization requirements continue to be a barrier, although they are decreasing.

Company Guidance -

Q2 2025

During ARS Pharmaceuticals' first quarter 2025 earnings call, the company provided guidance highlighting several key metrics. The launch of neffy, a needle-free epinephrine treatment, has shown promising results with first-quarter U.S. net product revenue of $7.8 million. Neffy addresses a market potential of $3 billion in net sales, targeting approximately 6.5 million prescribed patients and an additional 13.5 million diagnosed patients without prescriptions. The company has achieved 57% commercial insurance coverage, up from 27% at the start of the year, and expects further demand growth with an upcoming direct-to-consumer campaign. The 1-milligram pediatric dose has also been approved and represents 23% of all epinephrine units dispensed in 2024. ARS is expanding its commercial reach through a collaboration with ALK-Abelló, aiming to target over 20,000 healthcare providers, including 9,000 pediatricians, to strengthen neffy's position as a leading epinephrine option. The company is also anticipating regulatory reviews and potential launches in the U.K., Canada, Japan, China, and Australia from mid-2025 through the first half of 2026.

Neffy Launch and Market Potential

Neffy, the first needle-free epinephrine treatment, launched with a potential $3 billion net sales target in the U.S. market. It addresses significant unmet needs, gaining traction as a new standard of care.

Revenue Growth

Neffy generated $7.8 million in U.S. net product revenue in Q1 2025, with a total revenue of $8 million, indicating a strong market entry.

Insurance Coverage Expansion

Commercial insurance coverage for Neffy increased from 27% to 57%, with ongoing payer discussions expected to further increase coverage.

Successful Strategic Collaboration

ARS expanded a strategic collaboration with ALK-Abelló, enhancing commercial reach to over 20,000 healthcare providers, including 9,000 pediatricians.

Approval and Launch of Pediatric Dose

Neffy 1-milligram dose was approved by the FDA and launched for children, representing 23% of all epinephrine units dispensed in 2024.

Planned Direct-to-Consumer Campaign

A comprehensive DTC campaign, 'Hello neffy, Goodbye Needles', is set to launch, targeting a 95% reach of severe allergy patients and their caregivers.

ARS Pharmaceuticals (SPRY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SPRY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.46 / -	-0.13	―	―	―
May 14, 2025	2025 (Q1)	-0.34 / -0.35	-0.11	-218.18% (-0.24)	―
Mar 20, 2025	2024 (Q4)	-0.24 / 0.48	-0.07	785.71% (+0.55)	―
Nov 13, 2024	2024 (Q3)	-0.14 / -0.20	-0.16	-25.00% (-0.04)	―
Aug 06, 2024	2024 (Q2)	-0.11 / -0.13	-0.18	27.78% (+0.05)	―	―
May 09, 2024	2024 (Q1)	-0.10 / -0.11	-0.16	31.25% (+0.05)	―	―
Mar 21, 2024	2023 (Q4)	-0.14 / -0.07	-0.26	73.08% (+0.19)	―	―
Nov 09, 2023	2023 (Q3)	-0.18 / -0.16	-0.5	68.00% (+0.34)	―	―
Aug 10, 2023	2023 (Q2)	-0.17 / -0.18	-0.553	67.45% (+0.37)	―	―
May 15, 2023	2023 (Q1)	-0.16 / -0.16	-0.7	77.14% (+0.54)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SPRY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$13.35	$12.10	-9.36%
Mar 20, 2025	$11.65	$14.31	+22.83%
Nov 13, 2024	$16.61	$14.08	-15.23%
Aug 06, 2024	$9.78	$9.56	-2.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ars Pharmaceuticals, Inc. (SPRY) report earnings?

Ars Pharmaceuticals, Inc. (SPRY) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is Ars Pharmaceuticals, Inc. (SPRY) earnings time?

Ars Pharmaceuticals, Inc. (SPRY) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SPRY EPS forecast?

SPRY EPS forecast for the fiscal quarter 2025 (Q2) is -0.46.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing